Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alfoatirin + Aripezil in Alzheimer's Dementia
NCT03441516Phase 4Unknown
- Sponsor
- Yuhan
- Start
- Apr 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alfuzosin in Alzheimer's disease (AD) (2 arms), sponsored by Yuhan. Primary endpoint: Alzheimer's Disease Assessment Scale-cognitive subscale at 24 weeks. Status: unknown.
02
Drugs
alfuzosin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03441516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03441516.